Potassium Glutamate for Injection
Function and Efficacy
When liver function is severely damaged, ammonia metabolism in the body is disordered, leading to hepatic coma. After intravenous infusion, this product can combine with excess ammonia in the blood to form non-toxic glutamine, which dissociates ammonia through the action of glutaminase in the kidneys and is excreted in the urine, thus alleviating the symptoms of hepatic coma. This product also participates in brain protein metabolism and sugar metabolism, promotes the oxidation process, and improves the function of the central nervous system.
Ingredients
Main ingredient: Potassium glutamate, chemical name: monopotassium salt of L-2-aminoglutaric acid
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| L-GLUTAMIC ACID MONOPOTASSIUM SALTIngredients |
When liver function is severely damaged, ammonia metabolism in the body is disordered, leading to hepatic coma. After intravenous infusion, this product can combine with excess ammonia in the blood to form non-toxic glutamine, which dissociates ammonia through the action of glutaminase in the kidneys and is excreted in the urine, thus alleviating the symptoms of hepatic coma. This product also participates in brain protein metabolism and sugar metabolism, promotes the oxidation process, and improves the function of the central nervous system. More |
19473-49-5 | 0 |
Appearance
This product is white or off-white lump or powder.
Indication
Used for hepatic encephalopathy, hepatic coma and other mental symptoms caused by excessive blood ammonia.
Usage and Dosage
Treatment of hepatic coma by intravenous drip: Dissolve 18.9g of potassium glutamate in 500-1000ml of 5% or 10% glucose injection and slowly drip once or twice a day. It is suitable for patients with hypokalemia. To maintain electrolyte balance, potassium glutamate is often used in combination with sodium glutamate in a ratio of 1:3 or 1:2.
Adverse Reactions
1. Too fast intravenous drip can cause salivation, skin flushing and vomiting. Tremors may occur in children. 2. During intravenous drip, attention should be paid to electrolyte balance, and blood carbon dioxide binding capacity and potassium, sodium and chloride levels should be measured when possible. 3. Patients with anxiety may experience syncope, tachycardia, tearing and nausea.
Precautions
Overdose of this product may cause alkalemia, so it should be used with caution or prohibited in patients with alkalemia.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
18.9g
Manufacturer
Shenyang EverBright Pharmaceutical Co., Ltd.
-
Founded in:
1999-01-22 -
Address:
No. 31, Songhuahu Street, Shenyang Economic and Technological Development Zone -
Tax NO.:
912101064107084581 -
Registered Funds:
8.82 million yuan -
Website:
-
Email: